Whistleblower Management: Rogue FDA Reviewer Sets Tone to Start Avandia Committee; Forgotten By End
This article was originally published in RPM Report
Executive Summary
Avandia has been a contentious topic for FDA for six years. The latest advisory committee review highlights how far the agency has come in handling dissent – but also underscores the impact that a lone voice can have on delaying reviews, and prompting damaging headlines.
You may also be interested in...
Meta-Analyses After Avandia: FDA Hopes To Set Standards And Controls
FDA is working on a guidance for meta-analysis to support safety reviews, and it clearly hopes to have an impact beyond the walls of White Oak.
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
A re-adjudication of cardiovascular events in the RECORD trial reassured members of a June 5-6 advisory committee that the study findings are reliable, but did not erase uncertainties about CV risk associated with rosiglitazone.
TMI from TIMI: Xarelto and the Trouble with Very Large Trials
With bigger clinical trials come potentially bigger problems. That, at least, is what sponsors of 15,000-plus trials in cardiovascular medicine are finding out. J&J/Bayer’s experience in late May with Xarelto for acute coronary syndrome is a case in point—and it also provides timely context for the surprising setback for another CV project, Pfizer/BMS' Eliquis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: